Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review

Abstract Baricitinib is an oral selective inhibitor of Janus kinase (JAK)1 and JAK2 that has proved effective and well tolerated in the treatment of rheumatoid arthritis (RA) in an extensive programme of clinical studies of patients with moderate-to-severe disease. In a phase 2b dose-ranging study o...

Full description

Bibliographic Details
Main Authors: Paul Emery, Patrick Durez, Axel J. Hueber, Inmaculada de la Torre, Esbjörn Larsson, Thorsten Holzkämper, Yoshiya Tanaka
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Baricitinib
Radiographic progression
Joint damage
Joint erosion
Online Access:https://doi.org/10.1186/s13075-020-02379-6

Internet

https://doi.org/10.1186/s13075-020-02379-6

Similar Items